MedPath

Galvanize Therapeutics, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:2

Trial Phases

2 Phases

Phase 4:1
Not Applicable:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Not Applicable
3 (75.0%)
Phase 4
1 (25.0%)

Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer

Not Applicable
Completed
Conditions
Lung Neoplasm Malignant
First Posted Date
2023-06-06
Last Posted Date
2025-08-20
Lead Sponsor
Galvanize Therapeutics, Inc.
Target Recruit Count
30
Registration Number
NCT05890872
Locations
🇺🇸

Mayo Clinic, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic Rochester, Rochester, Minnesota, United States

🇺🇸

Weill Cornell Medicine | New York-Presbyterian, New York, New York, United States

and more 2 locations

Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry

Recruiting
Conditions
Soft Tissue Lesion
First Posted Date
2023-05-09
Last Posted Date
2025-07-28
Lead Sponsor
Galvanize Therapeutics, Inc.
Target Recruit Count
200
Registration Number
NCT05851430
Locations
🇺🇸

Eisenhower Medical Center, Rancho Mirage, California, United States

🇺🇸

New York Presbyterian Langone Health, New York, New York, United States

🇺🇸

Duke University Hospital, Durham, North Carolina, United States

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Phase 4
Terminated
Conditions
NSCLC
Interventions
Device: Aliya Pulsed Electric Fields (PEF) ablation
Drug: Standard of care neoadjuvant therapy
Other: Surgical Resection
First Posted Date
2022-10-17
Last Posted Date
2024-07-19
Lead Sponsor
Galvanize Therapeutics, Inc.
Target Recruit Count
5
Registration Number
NCT05583188
Locations
🇺🇸

Mayo Clinic Rochester, Rochester, Minnesota, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Temple University, Philadelphia, Pennsylvania, United States

A Clinical Evaluation of the Aliya™ System in Late Stage Cancer

Not Applicable
Terminated
Conditions
Cancer of Lung, Kidney or Liver
First Posted Date
2021-02-26
Last Posted Date
2025-08-01
Lead Sponsor
Galvanize Therapeutics, Inc.
Target Recruit Count
4
Registration Number
NCT04773275
Locations
🇭🇰

Prince of Wales Hospital, Sha Tin, Hong Kong

🇳🇱

Radboud University Medical Center, Nijmegen, Netherlands

🇪🇸

Hospital Universitario de Salamanca, Salamanca, Spain

Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer

Not Applicable
Completed
Conditions
Non Small Cell Lung Cancer
First Posted Date
2021-02-01
Last Posted Date
2024-07-19
Lead Sponsor
Galvanize Therapeutics, Inc.
Target Recruit Count
47
Registration Number
NCT04732520
Locations
🇭🇰

Prince of Wales Hospital, Sha Tin, Hong Kong

🇳🇱

Radboud University Medical Center, Nijmegen, Netherlands

🇪🇸

Fundacion Instituto de Investigation Sanitaria de la Fundacion Jimenez Diaz, Madrid, Spain

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.